Trial Profile

A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 20 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Cisplatin
Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
Focus Registrational; Therapeutic Use
Acronyms KEYNOTE-A18
Sponsors Merck Sharp & Dohme

Most Recent Events

13 May 2025 According to a Merck Sharp & Dohme media release, data from this study will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (May 30-June 3).
08 Nov 2024 Planned End Date changed from 17 Jan 2025 to 17 Jan 2026.
08 Nov 2024 Planned primary completion date changed from 17 Jan 2025 to 7 Jan 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com